BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 11481600)

  • 1. Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure.
    Nakae H; Narita K; Endo S
    J Crit Care; 2001 Jun; 16(2):59-63. PubMed ID: 11481600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble Fas and soluble Fas L levels in patients with acute pancreatitis.
    Endo S; Inoue Y; Fujino Y; Yamada Y; Sato N; Wakabayashi G; Sakamoto T; Ishikura H; Tanaka T; Inada K; Sato S
    Res Commun Mol Pathol Pharmacol; 2000; 108(3-4):179-86. PubMed ID: 11913710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
    Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
    J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection.
    Raghuraman S; Abraham P; Daniel HD; Ramakrishna BS; Sridharan G
    J Clin Virol; 2005 Sep; 34(1):63-70. PubMed ID: 16087126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease.
    Takabatake N; Nakamura H; Inoue S; Terashita K; Yuki H; Kato S; Yasumura S; Tomoike H
    Respir Med; 2000 Dec; 94(12):1215-20. PubMed ID: 11192958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble Fas and soluble FasL in multiple organ dysfunction syndrome complicating diffuse peritonitis.
    Kitamura M; Endo S; Sato N; Yaegashi Y; Suxzuki Y; Kojika N; Wakabayashi G
    Res Commun Mol Pathol Pharmacol; 2004; 115-116():235-42. PubMed ID: 17564320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma.
    Murakami M; Sasaki T; Miyata H; Yamasaki S; Kuwahara K; Chayama K
    Oncol Rep; 2004 Jun; 11(6):1183-6. PubMed ID: 15138553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL.
    Jabłońska E; Kiersnowska-Rogowska B; Rogowski F; Parfieńczyk A; Puzewska W; Bukin M
    Rocz Akad Med Bialymst; 2005; 50():204-7. PubMed ID: 16358967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased serum soluble Fas in patients with acute liver failure due to paracetamol overdose.
    Tagami A; Ohnishi H; Hughes RD
    Hepatogastroenterology; 2003; 50(51):742-5. PubMed ID: 12828076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors.
    Kondera-Anasz Z; Mielczarek-Palacz A; Sikora J
    Apoptosis; 2005 Oct; 10(5):1143-9. PubMed ID: 16151647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. sFas and sFas ligand and pediatric sepsis-induced multiple organ failure syndrome.
    Doughty L; Clark RS; Kaplan SS; Sasser H; Carcillo J
    Pediatr Res; 2002 Dec; 52(6):922-7. PubMed ID: 12438671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
    Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O
    Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF.
    Onalan G; Selam B; Baran Y; Cincik M; Onalan R; Gündüz U; Ural AU; Pabuccu R
    Hum Reprod; 2005 Sep; 20(9):2391-5. PubMed ID: 15932917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour necrosis factor-alpha and soluble Fas ligand as biomarkers in non-acetaminophen-induced acute liver failure.
    Singhal S; Chakravarty A; Das BC; Kar P
    Biomarkers; 2009 Aug; 14(5):347-53. PubMed ID: 19505222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus.
    Song le H; Binh VQ; Duy DN; Bock TC; Kremsner PG; Luty AJ; Mavoungou E
    J Med Virol; 2004 Jun; 73(2):244-9. PubMed ID: 15122799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure.
    Ryo K; Kamogawa Y; Ikeda I; Yamauchi K; Yonehara S; Nagata S; Hayashi N
    Am J Gastroenterol; 2000 Aug; 95(8):2047-55. PubMed ID: 10950056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble Fas, Fas ligand and Bcl-2 in autoimmune thyroid diseases: relation to humoral immune response markers.
    Myśliwiec J; Okota M; Nikołajuk A; Górska M
    Adv Med Sci; 2006; 51():119-22. PubMed ID: 17357290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of soluble TNF receptor-I in acute-type fulminant hepatitis.
    Tokushige K; Yamaguchi N; Ikeda I; Hashimoto E; Yamauchi K; Hayashi N
    Am J Gastroenterol; 2000 Aug; 95(8):2040-6. PubMed ID: 10950055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of Fas and Fas ligand in tuberculous lymphadenitis.
    Mustafa T; Mogga SJ; Mfinanga SG; Mørkve O; Sviland L
    Immunology; 2005 Feb; 114(2):255-62. PubMed ID: 15667570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between plasma levels of cardiac natriuretic peptides and soluble Fas: plasma soluble Fas as a prognostic predictor in patients with congestive heart failure.
    Tsutamoto T; Wada A; Maeda K; Mabuchi N; Hayashi M; Tsutsui T; Ohnishi M; Fujii M; Matsumoto T; Yamamoto T; Takayama T; Kinoshita M
    J Card Fail; 2001 Dec; 7(4):322-8. PubMed ID: 11782855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.